Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Raw Materials (2016 - 2018)

Historic Raw Materials for Theravance Biopharma (TBPH) over the last 6 years, with Q3 2018 value amounting to $10.8 million.

  • Theravance Biopharma's Raw Materials rose 841.38% to $10.8 million in Q3 2018 from the same period last year, while for Sep 2018 it was $10.8 million, marking a year-over-year increase of 841.38%. This contributed to the annual value of $11.7 million for FY2017, which is 9332.45% up from last year.
  • Theravance Biopharma's Raw Materials amounted to $10.8 million in Q3 2018, which was up 841.38% from $10.6 million recorded in Q2 2018.
  • Over the past 5 years, Theravance Biopharma's Raw Materials peaked at $11.7 million during Q4 2017, and registered a low of $4.0 million during Q1 2014.
  • In the last 5 years, Theravance Biopharma's Raw Materials had a median value of $6.9 million in 2015 and averaged $7.6 million.
  • As far as peak fluctuations go, Theravance Biopharma's Raw Materials plummeted by 2193.75% in 2016, and later skyrocketed by 9332.45% in 2017.
  • Over the past 5 years, Theravance Biopharma's Raw Materials (Quarter) stood at $6.8 million in 2014, then increased by 0.57% to $6.9 million in 2015, then fell by 11.68% to $6.1 million in 2016, then skyrocketed by 93.32% to $11.7 million in 2017, then decreased by 8.05% to $10.8 million in 2018.
  • Its Raw Materials stands at $10.8 million for Q3 2018, versus $10.6 million for Q2 2018 and $10.6 million for Q1 2018.